Reasons for discontinuation from maintenance therapy
| . | Lenalidomide maintenance, n (%), n = 213 . | Median duration of maintenance, mo . |
|---|---|---|
| Ongoing (no discontinuation) | 63 (29.6) | 45.7 |
| Discontinued | 150 (70.4) | — |
| Progression or death | 52 (24.4) | 20.0 |
| Adverse events | 41 (19.2) | 11.7 |
| Reasons not due to progression, death, or adverse events* | 57 (26.8) | 21.2 |
| . | Lenalidomide maintenance, n (%), n = 213 . | Median duration of maintenance, mo . |
|---|---|---|
| Ongoing (no discontinuation) | 63 (29.6) | 45.7 |
| Discontinued | 150 (70.4) | — |
| Progression or death | 52 (24.4) | 20.0 |
| Adverse events | 41 (19.2) | 11.7 |
| Reasons not due to progression, death, or adverse events* | 57 (26.8) | 21.2 |
Completed treatment course, in remission, insurance change, withdrew consent, or other.